An oligoreview.

Here’s a review on the oligostudies in print prospectively evaluating consolidative local therapy for oligometastatic non-small cell lung cancer (NSCLC). And one thing not oligo in this commentary is the use of the prefix “oligo.” Anyway, it highlights three randomized studies: “oligomez” (n=73, closed early for clear benefit) and SABR-COMET (n=18 with NSCLC), of course, as well as a small phase 2 trial out of UT Southwestern (n=29, closed early for clear benefit). The best thing about this review are tables 1-2 that crystallize important variations among the designs and results of these trials as well as distinctions between eligibility criteria and actual characteristics of enrollees—the latter being the more relevant for clinical applications. TBL: To come to an interdisciplinary consensus on labeling consolidative radiation as standard of care for NSCLC with asymptomatic oligomets, we will all be doing ourselves a service to treat such patients on larger scale prospective trials in the setting of targeted therapies and immune checkpoint inhibitors. | Giuliani, Int J Radiat Oncol Biol Phys 2020


Popular Posts